Rallybio Announces RLYB212 And RLYB332 Preclinical Data At The 66th ASH Annual Meeting
Rallybio Announces RLYB212 And RLYB332 Preclinical Data At The 66th ASH Annual Meeting
Rallybio在第66屆ASH年會上發佈了RLYB212和RLYB332的臨床前數據
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California.
Rallybio公司（納斯達克：RLYB）是一家臨床階段的生物技術公司，將科學進展轉化爲改變患者生活的療法，今天宣佈將在2024年12月7日至10日在加利福尼亞州聖地亞哥舉行的第66屆美國血液學會（ASH）年會和博覽會上展示兩份海報，強調管線候選藥物RLYB212和RLYB332的前臨床數據具有良好前景。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。